NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today the release of a white paper titled “StereoCED™ - A Scalable Platform for CNS Drug Delivery,” which outlines the company's approach to addressing key barriers in the commercial delivery of brain therapeutics. The white paper is available for download from the Scientific Resources section of nmtc1.com.
The white paper highlights the growing demand for efficient and reproducible methods of delivering therapies directly to the brain, driven by advances in cell and gene therapies, biologics, and other central nervous system (CNS) therapeutics. Convection-enhanced delivery (CED) has been shown to bypass the blood-brain barrier and achieve targeted drug distribution, but current approaches may present challenges as therapies scale for broader commercial use. The StereoCED™ drug delivery platform is designed to overcome these challenges by integrating with robotic stereotactic systems already used in neurosurgical operating rooms. Instead of requiring specialized workflows and lengthy sequential infusions, the platform supports simultaneous, multi-trajectory intracranial drug delivery through a streamlined robotic workflow. This could significantly reduce procedure time while enabling reproducible and scalable therapeutic delivery.
“Brain-delivered therapeutics are approaching an important inflection point,” said Dave Rosa, President and Chief Executive Officer of NeuroOne. “As these therapies move toward commercialization, certain intracranial infusion procedures lasting 8 to 12 hours may become a significant bottleneck to commercial adoption. We believe healthcare systems will need solutions that leverage established neurosurgical workflows, significantly reduce procedure time, and support scalable delivery across hospitals. StereoCED™ is being designed with those needs in mind, and we look forward to device availability for research and investigational clinical studies by fiscal year-end.”
The StereoCED™ platform is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration for commercialization. NeuroOne is a medical technology company focused on improving surgical care for patients with neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations, lower costs, and improve patient outcomes. NeuroOne is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
The implications of this announcement are significant for the CNS therapeutics field. If successful, the StereoCED™ platform could remove a major bottleneck in the commercial adoption of brain-delivered therapies, potentially accelerating patient access to novel treatments. By reducing procedure times from hours to a more streamlined process, healthcare systems may be able to treat more patients efficiently. The platform's reliance on existing robotic systems could also facilitate adoption across hospitals without requiring extensive new infrastructure. However, the device remains in development and must still undergo regulatory review before it can be used commercially.
